系统性硬化症的极早期诊断：解读疾病极早期阶段系统性硬化症的异质性
Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease.
作者信息
Lescoat Alain
机构信息
Department of Internal Medicine and Clinical Immunology, CHU Rennes, University of Rennes 1, Rennes, France.
CHU Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail UMR_S 1085, Rennes, France.
出版信息
J Scleroderma Relat Disord. 2023 Feb;8(1):3-6. doi: 10.1177/23971983221129211. Epub 2022 Oct 11.
Abstract
The early diagnosis of systemic sclerosis has been a major challenge for the scleroderma community in the past 50 years. The recent publication of the predictive value of the VEDOSS (Very Early Diagnosis of Systemic Sclerosis) criteria in the in December 2021 has provided an unprecedented insight in the early stages of the disease. This editorial discusses the main findings from this 2021 VEDOSS publication and highlights key unanswered questions to be proposed on the research agenda in very early systemic sclerosis.
摘要
在过去50年里，系统性硬化症的早期诊断一直是硬皮病领域的一项重大挑战。2021年12月发表的关于系统性硬化症极早期诊断（VEDOSS）标准预测价值的研究，为该疾病的早期阶段提供了前所未有的见解。这篇社论讨论了2021年VEDOSS研究的主要发现，并强调了在系统性硬化症极早期研究议程上有待提出的关键未解决问题。
相似文献
1
Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease.
J Scleroderma Relat Disord. 2023 Feb;8(1):3-6. doi: 10.1177/23971983221129211. Epub 2022 Oct 11.
2
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
Lancet Rheumatol. 2021 Dec;3(12):e834-e843. doi: 10.1016/S2665-9913(21)00244-7.
3
Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.
Ann Rheum Dis. 2014 Dec;73(12):2087-93. doi: 10.1136/annrheumdis-2013-203716. Epub 2013 Aug 12.
4
A New Way of Thinking about Systemic Sclerosis: The Opportunity for a Very Early Diagnosis.
Isr Med Assoc J. 2016 Mar-Apr;18(3-4):141-3.
5
The frequency of Raynaud's phenomenon, very early diagnosis of systemic sclerosis, and systemic sclerosis in a large Veteran Health Administration database.
BMC Rheumatol. 2021 Oct 15;5(1):42. doi: 10.1186/s41927-021-00209-z.
6
Very Early Diagnosis of Systemic Sclerosis in Clinical Practice - Case Report and Review of the Literature.
Acta Dermatovenerol Croat. 2022 Dec;30(4):251-255.
7
8
From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey.
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):82-87. Epub 2018 Aug 29.
9
Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis.
J Rheumatol. 2017 Aug;44(8):1190-1197. doi: 10.3899/jrheum.160791. Epub 2017 May 15.
10
Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort.
Rheumatology (Oxford). 2022 Aug 30;61(9):3686-3692. doi: 10.1093/rheumatology/keac006.
引用本文的文献
1
Macrovascular Involvement in Systemic Sclerosis: Association Between Carotid Ultrasound Hemodynamics Parameters and Digital Ulcers.
Clin Pract. 2025 Aug 18;15(8):152. doi: 10.3390/clinpract15080152.
2
An international perspective on the future of systemic sclerosis research.
Nat Rev Rheumatol. 2025 Mar;21(3):174-187. doi: 10.1038/s41584-024-01217-2. Epub 2025 Feb 14.
3
Digital Ulcers and Microvascular Abnormalities Presenting As the Initial Manifestations of Pre-scleroderma.
Cureus. 2024 Dec 3;16(12):e75061. doi: 10.7759/cureus.75061. eCollection 2024 Dec.
4
Vascular endothelial growth factor as a potential biomarker in systemic sclerosis: a systematic review and meta-analysis.
Front Immunol. 2024 Nov 28;15:1442913. doi: 10.3389/fimmu.2024.1442913. eCollection 2024.
5
Gut microbiota in very early systemic sclerosis: the first case-control taxonomic and functional characterisation highlighting an altered butyric acid profile.
RMD Open. 2024 Nov 18;10(4):e004647. doi: 10.1136/rmdopen-2024-004647.
6
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
JAMA Dermatol. 2023 Aug 1;159(8):837-847. doi: 10.1001/jamadermatol.2023.1729.
本文引用的文献
1
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
Lancet Rheumatol. 2021 Dec;3(12):e834-e843. doi: 10.1016/S2665-9913(21)00244-7.
2
The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder.
Lancet Rheumatol. 2019 Dec;1(4):e257-e264. doi: 10.1016/S2665-9913(19)30038-4.
3
Towards preventive treatment of rheumatoid arthritis.
Lancet. 2022 Jul 23;400(10348):253-255. doi: 10.1016/S0140-6736(22)01327-7.
4
False positive anti-Topoisomerase I (Scl-70) antibody results in clinical practice: A case series from a scleroderma referral center.
Semin Arthritis Rheum. 2022 Oct;56:152052. doi: 10.1016/j.semarthrit.2022.152052. Epub 2022 Jun 17.
5
Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up.
Arthritis Rheumatol. 2022 Sep;74(9):1580-1587. doi: 10.1002/art.42152. Epub 2022 Jul 21.
6
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
Clin Rev Allergy Immunol. 2023 Jun;64(3):239-261. doi: 10.1007/s12016-021-08891-0. Epub 2021 Sep 1.
7
Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis.
Diagnostics (Basel). 2021 Jun 9;11(6):1064. doi: 10.3390/diagnostics11061064.
8
Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.
Arthritis Res Ther. 2021 Jun 14;23(1):170. doi: 10.1186/s13075-021-02548-1.
9
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
Expert Opin Investig Drugs. 2021 Jun;30(6):635-652. doi: 10.1080/13543784.2021.1923693. Epub 2021 May 13.
10
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort.
Rheumatology (Oxford). 2021 Nov 3;60(11):5028-5041. doi: 10.1093/rheumatology/keab152.
Zotero 插件